Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (NS38992)
Received: 21 February 2020
Accepted: 12 November 2020
First Online: 1 December 2020
: Dr. Mathern is partly supported by Thomas P. and Nadia Q. Davies Chair in honor of Paul H. Crandall, M, for Epilepsy Research, and The National Institutes of Health R01 NS38992.. Dr. Wu serves on the professional advisory board for the Tuberous Sclerosis Alliance; has received honoraria from and serves on the scientific advisory board and the speakers’ bureau for Novartis Pharmaceuticals Inc. and GW Pharmaceutical; and has received research support from the Tuberous Sclerosis Alliance, Novartis Pharmaceuticals Inc., Today and Tomorrow Children’s Fund, Department of Defense/Congressionally Directed Medical Research Program, and the NIH. All other authors report no disclosures relevant to the manuscript.